Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib

Brett Lauring, Xiujiang Li, Yang Liu, Christy Corr, Nicole Lazarus, Josee Cote, Patrick Larson, Amy O.Johnson Levonas, Kenneth C. Lasseter, Richard A. Preston, William Smith, Eseng Lai, John A. Wagner

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Two open-label, parallel-group studies evaluated the influence of renal and hepatic insufficiency on the pharmacokinetics of a single-dose anacetrapib 100 mg. Eligible participants included adult men and women with moderate hepatic impairment (assessed by Child-Pugh criteria) or severe renal impairment (CrCl <30 mL/min/1.73 m 2 ). In both studies, patients were matched (race, age, sex, BMI) with healthy control subjects. Twenty-four subjects were randomized in each study (12 with either moderate hepatic or severe renal impairment and 12 matched healthy controls). In the hepatic insufficiency study, the geometric mean ratio (GMR; mean value for the group with moderate hepatic insufficiency/mean value for the healthy controls) and 90% CIs for the area under the concentration-time curve from time zero to infinity (AUC 0- ) and the maximum concentration of drug in plasma (C max ) were 1.16 (0.84, 1.60) and 1.02 (0.71, 1.49), respectively. In the renal insufficiency study, the GMRs (mean value for the group with severe renal insufficiency/mean value for the healthy controls) and 90% CIs for AUC 0- and C max were 1.14 (0.80, 1.63) and 1.31 (0.93, 1.83), respectively. Anacetrapib was generally well tolerated and there was no clinically meaningful effect of moderate hepatic or severe renal insufficiency on the pharmacokinetics of anacetrapib.

Original languageEnglish (US)
Pages (from-to)1247-1255
Number of pages9
JournalJournal of Clinical Pharmacology
Volume54
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Hepatic Insufficiency
Renal Insufficiency
Pharmacokinetics
Kidney
Liver
Area Under Curve
Healthy Volunteers
anacetrapib
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Lauring, B., Li, X., Liu, Y., Corr, C., Lazarus, N., Cote, J., ... Wagner, J. A. (2014). Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. Journal of Clinical Pharmacology, 54(11), 1247-1255. https://doi.org/10.1002/jcph.320

Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. / Lauring, Brett; Li, Xiujiang; Liu, Yang; Corr, Christy; Lazarus, Nicole; Cote, Josee; Larson, Patrick; Levonas, Amy O.Johnson; Lasseter, Kenneth C.; Preston, Richard A.; Smith, William; Lai, Eseng; Wagner, John A.

In: Journal of Clinical Pharmacology, Vol. 54, No. 11, 01.11.2014, p. 1247-1255.

Research output: Contribution to journalArticle

Lauring, B, Li, X, Liu, Y, Corr, C, Lazarus, N, Cote, J, Larson, P, Levonas, AOJ, Lasseter, KC, Preston, RA, Smith, W, Lai, E & Wagner, JA 2014, 'Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib', Journal of Clinical Pharmacology, vol. 54, no. 11, pp. 1247-1255. https://doi.org/10.1002/jcph.320
Lauring, Brett ; Li, Xiujiang ; Liu, Yang ; Corr, Christy ; Lazarus, Nicole ; Cote, Josee ; Larson, Patrick ; Levonas, Amy O.Johnson ; Lasseter, Kenneth C. ; Preston, Richard A. ; Smith, William ; Lai, Eseng ; Wagner, John A. / Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. In: Journal of Clinical Pharmacology. 2014 ; Vol. 54, No. 11. pp. 1247-1255.
@article{90e6556427ca4f61bb616a881c2b5801,
title = "Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib",
abstract = "Two open-label, parallel-group studies evaluated the influence of renal and hepatic insufficiency on the pharmacokinetics of a single-dose anacetrapib 100 mg. Eligible participants included adult men and women with moderate hepatic impairment (assessed by Child-Pugh criteria) or severe renal impairment (CrCl <30 mL/min/1.73 m 2 ). In both studies, patients were matched (race, age, sex, BMI) with healthy control subjects. Twenty-four subjects were randomized in each study (12 with either moderate hepatic or severe renal impairment and 12 matched healthy controls). In the hepatic insufficiency study, the geometric mean ratio (GMR; mean value for the group with moderate hepatic insufficiency/mean value for the healthy controls) and 90{\%} CIs for the area under the concentration-time curve from time zero to infinity (AUC 0- ) and the maximum concentration of drug in plasma (C max ) were 1.16 (0.84, 1.60) and 1.02 (0.71, 1.49), respectively. In the renal insufficiency study, the GMRs (mean value for the group with severe renal insufficiency/mean value for the healthy controls) and 90{\%} CIs for AUC 0- and C max were 1.14 (0.80, 1.63) and 1.31 (0.93, 1.83), respectively. Anacetrapib was generally well tolerated and there was no clinically meaningful effect of moderate hepatic or severe renal insufficiency on the pharmacokinetics of anacetrapib.",
author = "Brett Lauring and Xiujiang Li and Yang Liu and Christy Corr and Nicole Lazarus and Josee Cote and Patrick Larson and Levonas, {Amy O.Johnson} and Lasseter, {Kenneth C.} and Preston, {Richard A.} and William Smith and Eseng Lai and Wagner, {John A.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1002/jcph.320",
language = "English (US)",
volume = "54",
pages = "1247--1255",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib

AU - Lauring, Brett

AU - Li, Xiujiang

AU - Liu, Yang

AU - Corr, Christy

AU - Lazarus, Nicole

AU - Cote, Josee

AU - Larson, Patrick

AU - Levonas, Amy O.Johnson

AU - Lasseter, Kenneth C.

AU - Preston, Richard A.

AU - Smith, William

AU - Lai, Eseng

AU - Wagner, John A.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Two open-label, parallel-group studies evaluated the influence of renal and hepatic insufficiency on the pharmacokinetics of a single-dose anacetrapib 100 mg. Eligible participants included adult men and women with moderate hepatic impairment (assessed by Child-Pugh criteria) or severe renal impairment (CrCl <30 mL/min/1.73 m 2 ). In both studies, patients were matched (race, age, sex, BMI) with healthy control subjects. Twenty-four subjects were randomized in each study (12 with either moderate hepatic or severe renal impairment and 12 matched healthy controls). In the hepatic insufficiency study, the geometric mean ratio (GMR; mean value for the group with moderate hepatic insufficiency/mean value for the healthy controls) and 90% CIs for the area under the concentration-time curve from time zero to infinity (AUC 0- ) and the maximum concentration of drug in plasma (C max ) were 1.16 (0.84, 1.60) and 1.02 (0.71, 1.49), respectively. In the renal insufficiency study, the GMRs (mean value for the group with severe renal insufficiency/mean value for the healthy controls) and 90% CIs for AUC 0- and C max were 1.14 (0.80, 1.63) and 1.31 (0.93, 1.83), respectively. Anacetrapib was generally well tolerated and there was no clinically meaningful effect of moderate hepatic or severe renal insufficiency on the pharmacokinetics of anacetrapib.

AB - Two open-label, parallel-group studies evaluated the influence of renal and hepatic insufficiency on the pharmacokinetics of a single-dose anacetrapib 100 mg. Eligible participants included adult men and women with moderate hepatic impairment (assessed by Child-Pugh criteria) or severe renal impairment (CrCl <30 mL/min/1.73 m 2 ). In both studies, patients were matched (race, age, sex, BMI) with healthy control subjects. Twenty-four subjects were randomized in each study (12 with either moderate hepatic or severe renal impairment and 12 matched healthy controls). In the hepatic insufficiency study, the geometric mean ratio (GMR; mean value for the group with moderate hepatic insufficiency/mean value for the healthy controls) and 90% CIs for the area under the concentration-time curve from time zero to infinity (AUC 0- ) and the maximum concentration of drug in plasma (C max ) were 1.16 (0.84, 1.60) and 1.02 (0.71, 1.49), respectively. In the renal insufficiency study, the GMRs (mean value for the group with severe renal insufficiency/mean value for the healthy controls) and 90% CIs for AUC 0- and C max were 1.14 (0.80, 1.63) and 1.31 (0.93, 1.83), respectively. Anacetrapib was generally well tolerated and there was no clinically meaningful effect of moderate hepatic or severe renal insufficiency on the pharmacokinetics of anacetrapib.

UR - http://www.scopus.com/inward/record.url?scp=85027936131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027936131&partnerID=8YFLogxK

U2 - 10.1002/jcph.320

DO - 10.1002/jcph.320

M3 - Article

VL - 54

SP - 1247

EP - 1255

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 11

ER -